加载中
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
最新数据
JP¥782
+JP¥45.00 · +6.11%
盘中时间采用JST。市场数据可能有所延迟。
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
日内区间
当前JP¥782
52周区间
当前JP¥782
盘中时间采用JST。市场数据可能有所延迟。
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
日内区间
当前JP¥782
52周区间
当前JP¥782
营业利润
净利润
| 项目（JPY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 8.2亿 JPY | 9.84亿 JPY | 6.71亿 JPY | 6.08亿 JPY |
| 毛利 | — | −8.2亿 JPY | −9.84亿 JPY | −6.71亿 JPY | −6.08亿 JPY |
| 研究与开发 | 10.57亿 JPY | 8.2亿 JPY | 9.83亿 JPY | 6.71亿 JPY | 6.08亿 JPY |
| 销售、一般及管理费用 | 3.01亿 JPY | 2.89亿 JPY | 1.91亿 JPY | 2.95亿 JPY | 1.75亿 JPY |
| 营业费用 | 13.58亿 JPY | 11.09亿 JPY | 2.78亿 JPY | 9.66亿 JPY | 8.46亿 JPY |
| 利息收入 | 445.7万 JPY | 141.2万 JPY | 3.2万 JPY | 2.1万 JPY | 1.7万 JPY |
| 利息支出 | — | — | — | 116.9万 JPY | 568万 JPY |
| 折旧和摊销 | — | 11.09亿 JPY | 12.62亿 JPY | — | — |
| 营业利润 | −13.58亿 JPY | −11.09亿 JPY | −12.62亿 JPY | −9.66亿 JPY | −8.46亿 JPY |
| 净利润 | −13.09亿 JPY | −11.57亿 JPY | −12.09亿 JPY | −12.44亿 JPY | −8.56亿 JPY |
公司数据更新于 2026年10月18日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
